Filing Flows › Integrated Biopharma (INBP) › Q4 FY26 › vs Q4 FY25
Integrated Biopharma (INBP) Q4 FY26 vs Q4 FY25 (year over year)
Integrated Biopharma's revenue fell $4.4M (-31%) from $14.2M in Q4 FY25 to $9.8M in Q4 FY26.
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart draws each line against Q4 FY25, the increases inside each band.
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $9.8M | $14.2M | −$4.4M | -31% |
| Net loss | $1.4M | $178K | $1.2M | +667% |
| Costs & expenses | $11.2M | $14.4M | −$3.2M | -22% |
| Operating costs | $10.7M | $13.6M | −$2.9M | -22% |
| Income tax | $516K | $773K | −$257K | -33% |
| Cost of revenue | $9.8M | $12.7M | −$2.9M | -23% |
| Operating expenses | $897K | $880K | $17K | +2% |
| Operating cash sources | $1.4M | $178K | $1.2M | +667% |
| Depreciation | $70K | $71K | −$1K | -1% |
| Share-based compensation | $51K | $44K | $7K | +16% |
| Working capital & other | $51K | $654K | −$603K | -92% |
| Cash used in operations | $1.2M | −$591K | $1.8M | — |
| Net loss absorbed | $1.4M | $178K | $1.2M | +667% |
Questions
How much did Integrated Biopharma's revenue grow year over year in Q4 FY26?
Integrated Biopharma's revenue fell $4.4M (-31%) from $14.2M in Q4 FY25 to $9.8M in Q4 FY26.